US-based clinical-stage biopharmaceutical company Bexion Pharmaceuticals Inc announced on Thursday the publication of first-in-human data from a Phase 1 study of its lead drug candidate BXQ-350 in Clinical Cancer Research, an American Association of Clinical Research (AACR) journal.

BXQ-350 is being studied for the first line treatment of metastatic colorectal cancer (mCRC). The study showed that the therapy was well-tolerated with no dose-limiting toxicities.

The publication highlights adverse event and efficacy data, including multiple patients who survived more than six months without disease progression. The study enrolled 86 patients across over 20 different tumour types, including advanced metastatic disease and high-grade glioma. Preliminary PK data showed that BXQ-350 exhibited linear exposure, crossing the blood-brain barrier and accumulating in relevant tissues.

The Phase 1b/2 trial is evaluating BXQ-350 in combination with the standard of care in newly diagnosed patients with mCRC.